top of page

Research Foundation

Cure Lyme NOW

Cure Lyme and Bartonella NOW


BioNeoMed is a registered non-profit 501(c)(3) organization. We are a group of nationally known doctors, patients, and world-class scientists committed to curing Lyme, Bartonella, and Babesia NOW. Through supporting cutting-edge research and developing therapeutic agents, we aim to improve diagnosis, treatment, and to ultimately find a cure. BioNeoMed is 100% volunteer operated so there are no overhead costs and 95% of the funds donated go directly to research.


 Dr. Kenneth Liegner and Dr. Daniel Kinderlehrer comprise the scientific advisory board. Dr. Liegner was the first doctor to prescribe disulfiram to patients suffering from Lyme disease. Disulfiram (Antabuse) is a 70-year-old generic drug that is used to treat alcoholism. After seeing disulfiram’s potent action against Lyme disease, Dr. Liegner published a groundbreaking case study that has inspired doctors around the world to treat their Lyme patients with this unexpected, new therapy. Dr. Kinderlehrer is a nationally known Lyme Literate Medical Doctor (LLMD) and an early adopter of using disulfiram to treat Lyme. Joseph Kulandai, MEngSc, a scientist, entrepreneur, and Facebook moderator for a Bartonella group, is heading the patient advocacy committee

About Us

BioNeoMed Research

BioNeoMed funds top research scientists at major institutions who are working to improve the diagnosis and treatment of Lyme and other vector-borne diseases. Funds are distributed after our board of directors carefully evaluate the impact that a proposed research project will have on BioNeoMed’s mission: to cure Lyme, Bartonella, and Babesia NOW.


BioNeoMed has supported the scientists that discovered the efficacy of disulfiram against Lyme. In 2016, scientists found that disulfiram could eradicate Borrelia bergdorferi (Lyme) in a test tube. Since then, our scientists have continued to conduct further research on disulfiram. Through cutting-edge research, they hope to find other novel treatments for Lyme, Bartonella, and Babesia. Our scientists are working on research that will impact a patient NOW – not ten years from now. We are excited to be funding researchers that bring us closer to having a cure.


Our mission is urgent. Lyme disease has spread throughout the world and is the number one vector-borne disease. Totalling an estimated 470,000 new cases a year in the US alone, Lyme disease is bigger than breast cancer and AIDS combined. This hidden epidemic is a worldwide crisis.


Bartonella has been considered a co-infection of Lyme but recent research indicates that Bartonella is often the primary infection and can cause severe disease manifestations in individuals without Lyme. Bartonella is thought to play a much bigger role in chronic illness than currently is appreciated and it is difficult to successfully treat. Babesia, also a co-infection of Lyme, is a parasite spread by ticks that can complicate a Lyme patient’s symptomology and treatment. The prevalence of these two infections is not well established.


Lyme and other vector-borne diseases are grossly underfunded and millions of people continue to suffer. Private foundations have funded the majority of Lyme and vector-borne disease research. Unfortunately, this funding is inadequate to address this epidemic. More research is needed so that we can find a cure NOW.


Here is a summary of current research that needs our support to continue:



  • How to avoid side effects of disulfiram including neuropathy and psychosis. Although considered rare, these side effects are being reported at higher rates among patients using disulfiram off-label for Lyme than patients using it on-label. Our researchers will investigate the reasons for the seemingly higher prevalence of side effects in Lyme patients.

  • Investigating the role of copper and other factors that may cause these side effects.

  • Mechanism and causes of inflammation and how to prevent them.



  • Testing a low dosing strategy of disulfiram in mice to investigate efficacy. Finding the lowest therapeutic dose in order to mitigate side effects.



  • High-throughput screening of antimicrobial candidates, including disulfiram and its derivatives, against Bartonella and Babesia. High-throughput screening is a method of scientific experimentation that screens a large compound library against biological targets. Our scientists have already completed this process for Borrelia.



  • The development of new, proprietary technology for the rapid diagnosis and monitoring of treatment and progression of Lyme disease.

Contact Us

Contact BioNeoMed Research Foundation

501(3)c ID # 83-2326718
1796 Brighten Ave, San Jose, CA 95124.

Thanks for submitting!

bottom of page